A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-05. Anything still debated is marked as such rather than presented as settled.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Positive autoantibody titres at a dilution equal to or greater than 1:160 are usually considered as clinically significant. Positive titres of less than 1:160 are present in up to 20% of the healthy population, especially the elderly. Although positive titres of 1:160 or higher are strongly associated with autoimmune disorders, they are also found in 5% of healthy individuals. Autoantibody screening is useful in the diagnosis of autoimmune disorders and monitoring levels helps to predict the progression of disease. A positive ANA test is seldom useful if other clinical or laboratory data supporting a diagnosis are not present.
For both existing and new customers, these costs of meeting AML/CFT obligations regularly outweigh the potential benefits for the financial institutions. Debanking affects commercial and personal users of financial institutions. A report by the FATF pointed out that access to financial services is essential for full participation in modern societies as well being a critical pre-condition for a well-functioning economy. If debanked, companies or individuals lose access to the financial system, making trade, investment, asset management and day-to-day activities difficult. The report noted that there had also been a growth in financial exclusion, due to debanking, amongst the poor, deprived groups, minorities, the elderly, the disabled and NPOs. There is no precise measurement of the full extent of the complex economic and social costs of regulation, including debanking, balanced against the scale of harms associated with money laundering, and given the evaluation problems involved in assessing such an issue, it is unlikely that the effectiveness of terror finance and money laundering laws could be determined with any degree of accuracy. Because of the intrinsic uncertainties of the amount of money laundered, changes in the amount of money laundered, and the cost of anti–money laundering systems, it is almost impossible to tell which anti–money laundering systems work and which are more or less cost effective.
== Prevalence == Hemoglobin D is most abundant among Sikhs, with occurrence of 2% in Punjab and 1% in Gujarat. It is also found in small number of individuals among Africans, Americans and Europeans who usually had close ethnicity with Indians in the past. It is below 2% among African-Americans. Combination with β-thalassemia and HbS are known in south and east India; the first resulting in thalassemia and the latter in sickle cell anemia. There is also high occurrence in China, with prevalence rate of 12.5% in Chongqing. It is sporadically recorded in some Turkish, Algerian, West African, Saudi Arabian, native American, English, and Irish population. Rare conditions like HbD/HbJ, HbD/ HbQ, and HbD/Hb Fontainebleau are also found in India. A rare case of HbS/HbD is reported from Pakistan in which individuals are diagnosed with bone infection (osteomyelitis). An isolated condition of HbD/HbC is recorded in US.
Scans conducted during the studies showed that Sharrock's brain exhibited a heightened connection between the conscious and sub-conscious parts of her brain, which may aid easier memory recall – in particular for events that took place earlier in life. In December 2017, a man named Joey DeGrandis was verified as having HSAM by James McGaugh and subsequently featured in an article in Time magazine. DeGrandis also reports having poor short-term memory, indicating that HSAM does not necessarily improve one's short-term memory abilities. A 63-year-old man, anonymised as "The Amazing Memory Man" (MM) was featured in a paper by Neuropsychology in March 2018, where it is reported that he "appreciates that his memory for personally experienced life events and general knowledge are both exceptional, whereas his imaging the future is only average" (after scoring 123 on Episodic, 123 on Semantic, 112 on Spatial, and 91 on Future remembering memory types, all with a mean of 100). In October 2018, it was reported that teenager Tyler Hickenbottom, who is an identical twin, had the condition, which allowed him to "remember every day of his life like it was yesterday". Tim Rogers, an American video game developer and journalist, claims to experience the condition in several of his published works. John Romero, a video game developer and co-founder of id Software, has often said he has hyperthymesia, including in his 2023 autobiography, Doom Guy: Life in First Person. In 2024, Emily Nash, an 18-year-old high school student with HSAM, was featured in a CTV W5 story.
Sources: en.wikipedia.org
Unlike David, who was warmly welcomed as a family member, Roseanne and the rest of the family only grudgingly accept Mark into their clan while still insulting him. Mark is not ungrateful to the Conners, however, and reveals to David, just before David's wedding to Darlene, that he considers Dan and Roseanne as being their parents now. Mark and David have two younger sisters, Lisa and Nikki, who are briefly seen in the Season 5 episode, "No Place Like Home for The Holidays". In season 10, Mark is now deceased, leaving Becky a financially-strapped and lonely widow. Actor Glenn Quinn had died between the original series and the revival, and it was decided not to recast his role. No further information was initially given about when and how Mark died, though Darlene and David's son, who was about ten years old during Season 10, was named in Mark's memory. It is eventually revealed in a Season 3 episode of The Conners that Mark was killed in a motorcycle crash.
Ian Hamley (born 1965) is a British academic who is the Diamond Professor of Physical Chemistry at the University of Reading. He is a soft matter scientist and physical chemist with research expertise in self-assembling molecules including polymers, peptides and other biomolecules. He has more than 400 published scientific papers. He is the author of 'The Physics of Block Copolymers', 'Introduction to Soft Matter', 'Block Copolymers in Solution', 'Introduction to Peptide Science', and 'Small-Angle Scattering: Theory, Instrumentation, Data and Applications', as well as several edited texts.
==== Antagonists ==== Cyclazocine Diprenorphine Levallorphan Nalodeine Nalorphine Naloxone Naltrexone Samidorphan Note that some of the above drugs may actually be very weak partial agonists rather than silent antagonists.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.